by nms-sync | Nov 22, 2023 | News
Nerviano_2023-09-01_NerPharMa Srl (NerPharMa), a leading Contract Development and Manufacturing Organization (CDMO), is pleased to announce the appointment of Claudio Salvagnini as the Deputy CEO, effective immediately.
Since Claudio joined the leadership...
by nms-sync | Sep 1, 2023 | News
Nerviano_2023-09-01_NerPharMa Srl (part of NMS group), a leading Contract Development and Manufacturing Organization (CDMO), is pleased to announce the appointment of Vittorio Montanaro as new Head of Quality, effective immediately. In this role, Vittorio will lead...
by nms-sync | Apr 5, 2023 | News
Nerviano, 05/04/2023
NMS Group certificato di nuovo come “Luogo di lavoro che promuove salute” nel 2022
NMS group dal 2017 aderisce con gran orgoglio al programma WHP , progetto di Regione Lombardia e ATS Città Metropolitana di Milano che si pone...
by nms-sync | Jan 10, 2023 | News
Nerviano, 9 January 2023 NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces the appointment of Ms. Sidney Dung as Chief Operating Officer with immediate effect. Ms. Dung, currently a member of the Company’s Executive Leadership...
by nms-sync | Oct 1, 2022 | News
NerPharMa Srl Announces Change in Board Composition Effective Today
Nerviano_October_1_2022_NerPharMa Srl, leading CMO and a member of the NMS Group today announced the change in its Board Composition, following the resignation of its board member Enrico...
by nms-sync | Jun 29, 2022 | News
The Board of Directors of NMS Group S.p.A has approved today the company’s annual financial report, including the consolidated financial statements of the Group as of 31 December 2021.
“2021 was a challenging yet rewarding year for our Group. As we firmly believe...
Recent Comments